Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M. Silverberg JI, et al. Among authors: myers de. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1797-1810. doi: 10.1111/jdv.17351. Epub 2021 Jun 12. J Eur Acad Dermatol Venereol. 2021. PMID: 33991374 Free PMC article. Review.
Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
Eichenfield LF, Yosipovitch G, Stein Gold LF, Kalabis M, Zang C, Vlahos B, Sanders P, Myers DE, Bushmakin AG, Cappelleri JC, Olivadoti M, Paller AS. Eichenfield LF, et al. Among authors: myers de. Pediatr Dermatol. 2020 Nov;37(6):1030-1037. doi: 10.1111/pde.14328. Epub 2020 Sep 27. Pediatr Dermatol. 2020. PMID: 32981097 Free PMC article. Clinical Trial.
Relationship Among Treatment, Pruritus, Investigator's Static Global Assessment, and Quality of Life in Patients with Atopic Dermatitis.
Simpson EL, Tom WL, Bushmakin AG, Cappelleri JC, Yosipovitch G, Ständer S, Luger T, Sanders P, Gerber RA, Myers DE. Simpson EL, et al. Among authors: myers de. Dermatol Ther (Heidelb). 2021 Apr;11(2):587-598. doi: 10.1007/s13555-021-00506-y. Epub 2021 Mar 9. Dermatol Ther (Heidelb). 2021. PMID: 33751495 Free PMC article.
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI, Thyssen JP, Simpson EL, Yosipovitch G, Ständer S, Valdez H, Rojo R, Biswas P, Myers DE, Feeney C, DiBonaventura M. Silverberg JI, et al. Among authors: myers de. Am J Clin Dermatol. 2021 Jul;22(4):541-554. doi: 10.1007/s40257-021-00604-9. Epub 2021 May 5. Am J Clin Dermatol. 2021. PMID: 33954933 Free PMC article. Clinical Trial.
Patient and caregiver preferences on treatment attributes for atopic dermatitis.
Ervin C, Crawford R, Evans E, Feldman SR, Zeichner J, Zielinski MA, Cappelleri JC, DiBonaventura M, Takiya L, Myers DE. Ervin C, et al. Among authors: myers de. J Dermatolog Treat. 2022 Jun;33(4):2225-2233. doi: 10.1080/09546634.2021.1940810. Epub 2021 Oct 6. J Dermatolog Treat. 2022. PMID: 34264145
Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI, Thyssen JP, Simpson EL, Yosipovitch G, Ständer S, Valdez H, Rojo R, Biswas P, Myers DE, Feeney C, DiBonaventura M. Silverberg JI, et al. Among authors: myers de. Am J Clin Dermatol. 2021 Sep;22(5):739. doi: 10.1007/s40257-021-00634-3. Am J Clin Dermatol. 2021. PMID: 34406620 Free PMC article. No abstract available.
Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE.
Gooderham MJ, Chu CY, Rojo R, Valdez H, Biswas P, Cameron MC, Feeney C, Encinas GA, Peeples-Lamirande K, Cappelleri JC, Myers DE, DiBonaventura M. Gooderham MJ, et al. Among authors: myers de. JAAD Int. 2021 Jul 1;4:46-48. doi: 10.1016/j.jdin.2021.05.004. eCollection 2021 Sep. JAAD Int. 2021. PMID: 34409391 Free PMC article. No abstract available.
Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.
Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G, Zhang F, Myers DE, DiBonaventura M. Cork MJ, et al. Among authors: myers de. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):422-433. doi: 10.1111/jdv.17792. Epub 2021 Dec 4. J Eur Acad Dermatol Venereol. 2022. PMID: 34743361 Free PMC article. Clinical Trial.
Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.
Thyssen JP, Yosipovitch G, Paul C, Kwatra SG, Chu CY, DiBonaventura M, Feeney C, Zhang F, Myers D, Rojo R, Valdez H. Thyssen JP, et al. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):434-443. doi: 10.1111/jdv.17813. Epub 2021 Dec 13. J Eur Acad Dermatol Venereol. 2022. PMID: 34779063 Free PMC article. Clinical Trial.
189 results